Last reviewed · How we verify
anti-GPC3 CAR-T cells — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
anti-GPC3 CAR-T cells (anti-GPC3 CAR-T cells) — Beijing Immunochina Medical Science & Technology Co., Ltd..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| anti-GPC3 CAR-T cells TARGET | anti-GPC3 CAR-T cells | Beijing Immunochina Medical Science & Technology Co., Ltd. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- anti-GPC3 CAR-T cells CI watch — RSS
- anti-GPC3 CAR-T cells CI watch — Atom
- anti-GPC3 CAR-T cells CI watch — JSON
- anti-GPC3 CAR-T cells alone — RSS
Cite this brief
Drug Landscape (2026). anti-GPC3 CAR-T cells — Competitive Intelligence Brief. https://druglandscape.com/ci/anti-gpc3-car-t-cells. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab